US EditionPublished • loading... • Updated
Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025
Summary by Charleston Gazette-Mail
26 Articles
26 Articles
LoudounTimes.com+25 Reposted by 25 other sources
Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025
BETHESDA, Md., Nov. 5, 2025 /PRNewswire/ -- Precision Biologics, Inc. announces in vitro and in vivo efficacy of its novel tumor-specific ADC (PB-vcMMAE-5) against human carcinomas expressing truncated core 2 O-glycans. Recent data for several human cancer types expressing truncated…
Coverage Details
Total News Sources26
Leaning Left2Leaning Right3Center8Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
15%
C 62%
R 23%
Factuality
To view factuality data please Upgrade to Premium
